finance
Kardigan Files for U.S. IPO to Fund Three Late-Stage Cardiovascular Drugs
Kardigan submitted paperwork for a U.S. initial public offering. The filing states the proceeds will support three late-stage drug candidates aimed at the underlying mechanisms of cardiovascular disease.
May 26, 5:54 PM·1m read1 source
BloombergAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
U.S. initial public offering. The company stated that funds raised will support development of three late-stage drug candidates designed to address root causes of cardiovascular diseases.
U.S. securities regulators.
Kardigan indicated the offering will provide capital for ongoing clinical programs without specifying share count or pricing range.
The three candidates target biological pathways linked to cardiovascular conditions. Kardigan described the programs as late-stage, indicating they have advanced through earlier safety and dosing studies. No timeline for completion of trials or regulatory submissions was included in the filing.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationLimited · 1 source
